Preclinical evaluation in nonhuman primates of murine monoclonal anti- idiotype antibody that mimics the disialoganglioside GD2

Clinical Cancer Research

Volumn 3, Issue 11, 1997, Pages 1969-1976

  Sen, Goutam ^b   Chakraborty, Mala ^b   Foon, Kenneth A ^b   Reisfeld, Ralph A ^c   Bhattacharya Chatterjee, Malaya ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE ANTIBODY; IDIOTYPIC ANTIBODY;

ANIMAL CELL; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MONKEY; MOUSE; NEUROECTODERM TUMOR; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COLONIC NEOPLASMS; GANGLIOSIDES; HUMANS; MACACA FASCICULARIS; MELANOMA; MICE; MICE, INBRED BALB C; RABBITS; TUMOR CELLS, CULTURED;

EID: 0030678011     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Hakomori, S. I. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res., 45: 2405-2414, 1985.
2. Hamilton, W. B., Helling, F., Lloyd, K. O., and Livingston, P. O. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin layer chromatography. Int. J. Cancer., 53: 566-573, 1993.
3. Tsuchida, T., Saxton, R. E., Morton, D. L., and Irie, R. F. Gangliosides of human melanoma. J. Natl. Cancer Inst., 78: 45-54, 1987.
4. Oettgen, H. F. (ed.), Gangliosides and Cancer. Weinheim, Germany: Verlag Chemie, 1989.
5. Hakomori, S. I., and Kannagi, R. Glycospingolipids as tumor associated and differentiation markers. J. Natl. Cancer Inst., 71: 231-251, 1983.
6. Cheresh, D. A., Rosenberg, J., Mujoo, K., Hirschowitz, L., and Reisfeld, R. A., Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res., 46: 5112-5118, 1986.
7. Mujoo, K., Cheresh, D. A., Yang, H. M., and Reisfeld, R. A. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res., 47: 1098-1104, 1987.
8. Tai, T., Cahan, L. D., Tsuchida, T., Saxton, R., Irie, R. F., and Morton, D. L. Immunogenicity of melanoma associated gangliosides in cancer patients. Int. J. Cancer, 35: 607-612, 1985.
9. Cheung, N. K. V., Canete, A., Cheung, I. Y., Ye, J. N., and Liu, C. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int. J. Cancer, 54: 499-505, 1993.
10. Livingston, P. O. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev., 145: 147-166, 1995.
11. Cheung, N-K. V., Cheung, I. Y., Canete, A., Yeh, S. J., Kushner, B., Bonilla, M. A., Heller, G., and Larson, S. M. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res., 54: 2228-2233, 1994.
12. Handgretinger, R., Baader, P., Dopfer, R., Klingebiel, T., Reuland, P., Treuner, J., Reisfeld, R. A., and Niethammer, D. A Phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14G2a. Cancer Immunol. Immunother., 35: 199-204, 1992.
13. Saleh, M. N., Khazaeli, M. B., Wheeler, R. H., Dropcho, E., Liu, T., Urist, M., Miller, D. M., Lawson, S., Dixon, P., Russell, C. H., and LoBuglio, A. F. Phase I trial of murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res., 52: 4342-4347, 1992.
14. Cheung, N. K. V., Lazarus, H., Miraldi, F. D., et al. Ganglioside GD2 specific monoclonal antibody 3F8: a Phase I study in patients with neuroblastoma and malignant melanoma J. Clin. Oncol., 5: 1430-1440, 1987.
15. Handgretinger, R., Anderson, K., Lang, P., Dopfer, R., Klingebiel, T., Schrappe, M., Reuland, P., Gillies, S. D., Reisfeld, R. A., and Neithammer, D. A Phase I study of human/mouse chimeric anti-ganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur. J. Cancer, 31A: 261-267, 1995.
16. Saleh, M. N., Khazaeli, M. B., Wheeler, R. H. et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody Ch14.18 in patients with malignant melanoma. Hum. Antib. Hybrid., 3: 19-24, 1992.
17. Hank, J. A., Surfus, J., Gan, J., Chew, T. L., Hong, R., Tans, K., Reisfeld, R., Seeger, R. C., Reynolds, C. P., and Bauer, M. Treatment of neuroblastoma patients with anti-ganglioside GD2 antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J. Immunother., 75: 29-37, 1994.
18. Albertini, M. R., Gan, J., Jaeger, P., Hank, J. A., Storer, B., Schell, K., Rivest, T., Surfus, J., Reisfeld, R. A., Schiller, J. H., and Sondel, P. M. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. J. Immunother., 19: 278-295, 1996.
19. Cheresh, D. A., Harper, J. R., Schulz, G., and Reisfeld, R. A. Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc. Natl. Acad. Sci. USA, 81: 5767-5771, 1984.
20. Cheresh, D. A., Pierschbacher, M. D., Herzig, M. A., and Mujoo, K. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J. Cell Biol., 102: 688-696, 1986.
21. Bhattacharya-Chatterjee, M., Foon, K. A., and Köhler, H. Antiidiotype monoclonal antibodies as vaccines for human cancer. Int. Rev. Immunol., 7: 289-302, 1991.
22. Bhattacharya-Chatterjee, M., Foon, K. A., and Köhler, H. Idiotypic antibody immunotherapy of cancer. Cancer Immunol. Immunother., 38: 75-82, 1994.
23. Livingston, P. O., Adluri, S., Helling, F., Yao, T. J., Kensil, C. R., Newman, N. J., and Marciani, D. Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine, 12: 1275-1280, 1994.
24. Kensil, C. R., Patel, U., Lennick, M., and Merciani, D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria monila cortex. J. Immunol., 146: 431-437, 1991.
25. + cytotoxic T-lymphocyte responses. J. Immunol, 148: 2357-2362, 1992.
26. Chakraborty, M., Foon, K. A., Köhler, H., and Bhattacharya-Chatterjee, M. Preclinical evaluation in nonhuman primates of an antiidiotypic antibody that mimics the carcinoembryonic antigen. J. Immunother., 18: 95-103, 1995.
27. Chakraborty, M., Mookerjee, S., Foon, K. A., Kohler, H., Ceriani, R. L., and Bhattacharya-Chatterjee, M. Induction of human breast cancer specific antibody responses in cynomolgus monkeys by a murine monoclonal anti-idiotype antibody. Cancer Res., 55: 1525-1530, 1995.
28. Livingston, P. Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccines. Ann. N. Y. Acad. Sci., 690: 204-213, 1993.
29. Chattopadhyay, P., Starkey, J., Morrow, J. W., and Raychaudhuri, S. Murine monoclonal anti-idiotype antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys. Proc. Natl. Acad. Sci. USA, 89: 2684-2688, 1992.
30. Chapman, P. B., and Houghton, A. N. Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. J. Clin. Invest., 88: 186-192, 1991.
31. Saleh, M. N., Stapleton, J. D., Khazaeli, M. B., and LoBuglio, A. F. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J. Immunol., 151: 3390-3398, 1993.
32. Yamamoto, S., Yamamoto, T., Saxton, R. E., Hoon, D. S. B., and Irie, R. F. Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3. J. Natl. Cancer Inst., 82: 1757-1760, 1990.
33. Hastings, A., Morrison, S. L., Kanda, S., Saxton, R. E., and Irie, R. F. Production and characterization of a murine human chimeric anti-idiotype antibody that mimics ganglioside. Cancer Res., 52: 1681-1686, 1992.
34. McCaffery, M., Yao, T-J., Williams, L., Livingston, P. O., Houghton, A. N., and Chapman, P. B. Immunization of melanoma patients with BEC2 anti-Idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin. Cancer Res., 2: 679-686, 1996.
35. Mittelman, A., Chen, Z. J., Yang, H., Wang, G. Y., and Ferrone, S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with State IV melanoma. Proc. Natl. Acad. Sci. USA, 89: 466-470, 1992.